OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $10 | -99.9% | 3,390 | 0.0% | 0.01% | -28.6% |
| Q3 2022 | $14,000 | 0.0% | 3,390 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $14,000 | -17.6% | 3,390 | 0.0% | 0.01% | -12.5% |
| Q1 2022 | $17,000 | -29.2% | 3,390 | 0.0% | 0.01% | -27.3% |
| Q4 2021 | $24,000 | 0.0% | 3,390 | +41.8% | 0.01% | 0.0% |
| Q3 2021 | $24,000 | -29.4% | 2,390 | 0.0% | 0.01% | -31.2% |
| Q2 2021 | $34,000 | +61.9% | 2,390 | +91.2% | 0.02% | +33.3% |
| Q1 2021 | $21,000 | -19.2% | 1,250 | 0.0% | 0.01% | -29.4% |
| Q4 2020 | $26,000 | +160.0% | 1,250 | 0.0% | 0.02% | +112.5% |
| Q3 2020 | $10,000 | 0.0% | 1,250 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $10,000 | +66.7% | 1,250 | 0.0% | 0.01% | +33.3% |
| Q1 2020 | $6,000 | -40.0% | 1,250 | -50.4% | 0.01% | -14.3% |
| Q4 2019 | $10,000 | +25.0% | 2,518 | 0.0% | 0.01% | +16.7% |
| Q3 2019 | $8,000 | -27.3% | 2,518 | 0.0% | 0.01% | -33.3% |
| Q2 2019 | $11,000 | – | 2,518 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,424 | $46,801,000 | 100.00% |
| Opaleye Management Inc. | 5,984,200 | $49,848,000 | 10.07% |
| DELTEC ASSET MANAGEMENT LLC | 2,330,267 | $19,411,000 | 4.06% |
| Corriente Advisors, LLC | 720,000 | $5,998,000 | 3.89% |
| Versant Venture Management, LLC | 2,215,384 | $18,454,145,000 | 2.65% |
| SV Health Investors, LLC | 312,068 | $2,600,000 | 1.80% |
| Ikarian Capital, LLC | 2,055,977 | $17,126,000 | 1.36% |
| EAM Global Investors LLC | 265,316 | $2,210,000 | 0.99% |
| EAM Investors, LLC | 346,075 | $2,883,000 | 0.64% |
| RA Capital Management | 2,727,272 | $22,718,000 | 0.44% |